Clinical Trials

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT07389616 2026-02-05

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Phase 2/3 Recruiting

40 enrolled

Lymphoma, T-Cell, Peripheral

NCT07356245 2026-01-21

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

DermatologicLymphoidOther hematologic neoplasm

44 enrolled

Graft vs Host Disease, Leukemia, Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07353840 2026-01-20

T-START-CR

160 enrolled

Pathologic Complete Response, Lymphoma, T-Cell, Peripheral

NCT06519526 2026-01-12

Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

25 enrolled

Lymphoma, T-Cell, Peripheral

NCT07093710 2025-12-31

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

Phase 1/2 Recruiting

101 enrolled

Lymphoma, T-Cell, Peripheral

NCT07253129 2025-12-23

T-START-PR

88 enrolled

Phase 3 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT07300514 2025-12-23

T-START-M1

136 enrolled

Phase 1/2 Not yet recruiting

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT07288814 2025-12-17

Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

43 enrolled

Recurrence, Lymphoma, T-Cell, Peripheral

NCT07283822 2025-12-16

Amping up With PemJAK

Phase 2 Not yet recruiting

53 enrolled

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT07279584 2025-12-12

Golidocitinib Combined With GemOx in RR PTCL

31 enrolled

Lymphoma, T-Cell, Peripheral

NCT07270861 2025-12-08

Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study

3,000 enrolled

Phase 1/2 Active not recruiting

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT02223208 2025-12-02

FIL_PTCL13

89 enrolled

Phase EARLY_PHASE1 Recruiting

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral

NCT07162012 2025-12-02

Anti-EBV TCR-T

24 enrolled

Phase 3 Enrolling by invitation

Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT07258680 2025-12-02

BrEto-TCL

114 enrolled

Lymphoma, T-Cell, Peripheral

NCT06176690 2025-11-13

CABAL2

Phase 1 Recruiting

90 enrolled

Phase 1/2 Not yet recruiting

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT07209163 2025-10-06

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

48 enrolled

Lymphoma, T-Cell, Peripheral

NCT04083495 2025-09-22

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

20 enrolled

DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, T-Cell, Peripheral

NCT02512497 2025-09-19

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Phase 1 Completed

23 enrolled

Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06160843 2025-09-05

POLAR

24 enrolled

Lymphoma, T-Cell, Peripheral

NCT04984837 2025-08-01

Study of Lacutamab in Peripheral T-cell Lymphoma

56 enrolled

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT03496779 2025-07-30

Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine

Phase 2 Completed

71 enrolled

Phase 2 Not yet recruiting

Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT07081607 2025-07-23

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

30 enrolled

Lymphoma, T-Cell, Peripheral

NCT07072221 2025-07-18

Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients

Phase NA Recruiting

40 enrolled

Phase 2 Not yet recruiting

Lymphoma, T-Cell, Peripheral

NCT07032532 2025-06-26

Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23)

35 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, T-Cell, Peripheral

NCT05290155 2025-06-06

Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies

Phase 1 Completed

14 enrolled

Immunoblastic Lymphadenopathy, Leukemia, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06244368 2025-05-14

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

115 enrolled

Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

NCT06963632 2025-05-09

JOYCE

Not yet recruiting

1,000 enrolled

Lymphoma, T-Cell, Peripheral

NCT03964480 2025-05-06

Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.

1,000 enrolled